A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC): Safety results.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e11097-e11097 ◽  
Author(s):  
W. Janni ◽  
T. Sarosiek ◽  
C. A. Papadimitriou ◽  
J. V. Álvarez Gallego ◽  
M. Caruso ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Randomized Trial ◽  
Phase Ii ◽  
Metastatic Breast ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC)

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 644-644 ◽  
Author(s):  
D. L. Graham ◽  
D. W. Hillman ◽  
T. J. Hobday ◽  
S. R. Rousey ◽  
S. G. Nair ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Breast ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

Trastuzumab and pertuzumab-based versus other therapy as second-line therapy in HER2-positive metastatic breast cancer: A retrospective study from single center.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 616-616
Author(s):  
Daniel Fontes Santos De Teive E Argolo ◽  
Lillian Mary Smyth ◽  
Neil M. Iyengar ◽  
Sujata Patil ◽  
Larry Norton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Retrospective Study ◽  
Metastatic Breast ◽  
Second Line ◽  
Single Center ◽  
Her2 Positive ◽  
Second Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document